Neurocrine Biosciences - NBIX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $128.52
  • Forecasted Upside: 16.68%
  • Number of Analysts: 21
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 16 Buy Ratings
  • 0 Strong Buy Ratings
▼ -1.64 (-1.47%)

This chart shows the closing price for NBIX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Neurocrine Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NBIX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NBIX

Analyst Price Target is $128.52
▲ +16.68% Upside Potential
This price target is based on 21 analysts offering 12 month price targets for Neurocrine Biosciences in the last 3 months. The average price target is $128.52, with a high forecast of $154.00 and a low forecast of $95.00. The average price target represents a 16.68% upside from the last price of $110.15.

This chart shows the closing price for NBIX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 21 investment analysts is to moderate buy stock in Neurocrine Biosciences. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 16 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 16 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 16 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 16 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 16 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 16 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 16 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 16 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 16 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/21/2023BarclaysBoost Target$125.00 ➝ $134.00Low
9/13/2023MizuhoReiterated RatingNeutral ➝ Neutral$113.00Low
9/13/2023Canaccord Genuity GroupBoost TargetBuy ➝ Buy$132.00 ➝ $144.00Low
9/13/2023Robert W. BairdBoost Target$148.00 ➝ $152.00Low
9/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$146.00Low
9/13/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$136.00Low
9/13/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$133.00 ➝ $134.00Low
9/13/2023WedbushBoost TargetOutperform ➝ Outperform$120.00 ➝ $137.00Low
9/13/2023BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$100.00 ➝ $111.00Low
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$136.00Low
8/21/2023MizuhoBoost TargetNeutral$112.00 ➝ $113.00Low
8/21/2023Jefferies Financial GroupBoost Target$123.00Low
8/21/2023OppenheimerBoost TargetOutperform ➝ Outperform$150.00 ➝ $154.00Low
8/21/2023HC WainwrightBoost TargetBuy ➝ Buy$140.00 ➝ $146.00Low
8/2/2023OppenheimerReiterated RatingOutperform ➝ Outperform$150.00Low
8/2/2023BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$96.00 ➝ $100.00Low
8/2/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$130.00N/A
8/2/2023Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$108.00 ➝ $110.00N/A
8/2/2023HC WainwrightReiterated RatingBuy ➝ Buy$140.00N/A
8/2/2023Canaccord Genuity GroupBoost TargetBuy ➝ Buy$130.00 ➝ $132.00Low
8/2/2023Cantor FitzgeraldBoost Target$127.00 ➝ $135.00Low
8/2/2023MizuhoBoost TargetNeutral ➝ Neutral$111.00 ➝ $112.00Low
8/2/2023Robert W. BairdBoost TargetOutperform ➝ Outperform$140.00 ➝ $148.00Low
7/24/2023SVB LeerinkUpgradeMarket Perform ➝ OutperformLow
7/24/2023SVB SecuritiesUpgradeMarket Perform ➝ Outperform$115.00 ➝ $125.00Low
7/6/2023BMO Capital MarketsUpgradeUnderperform ➝ Market Perform$91.00 ➝ $96.00Low
6/30/2023Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$108.00Low
6/6/2023Stifel NicolausLower Target$145.00 ➝ $125.00Low
6/5/2023Royal Bank of CanadaBoost Target$106.00 ➝ $108.00Low
5/4/2023MizuhoLower Target$116.00 ➝ $111.00Low
5/4/2023CitigroupLower Target$127.00 ➝ $122.00Low
5/4/2023BarclaysLower Target$131.00 ➝ $125.00Low
5/4/2023GuggenheimUpgradeNeutral ➝ Buy$145.00Low
4/24/2023Royal Bank of CanadaBoost Target$108.00 ➝ $110.00Low
4/19/2023CitigroupLower TargetBuy$131.00 ➝ $127.00Low
4/17/2023WedbushLower TargetOutperform$131.00 ➝ $128.00Low
4/14/2023MizuhoReiterated RatingNeutral$116.00Low
4/4/2023UBS GroupLower TargetBuy$137.00 ➝ $125.00Low
3/30/2023Canaccord Genuity GroupUpgradeHold ➝ Buy$124.00 ➝ $132.00Low
3/3/2023Evercore ISIUpgradeIn-Line ➝ Outperform$130.00Low
2/7/2023Royal Bank of CanadaLower TargetSector Perform$122.00 ➝ $110.00Low
2/7/2023Wells Fargo & CompanyLower TargetEqual Weight$120.00 ➝ $115.00Low
2/7/2023HC WainwrightReiterated RatingBuy$140.00Low
2/7/2023MizuhoReiterated RatingNeutral$116.00Low
2/7/2023Cantor FitzgeraldLower TargetOverweight$132.00 ➝ $127.00Low
2/7/2023WedbushBoost TargetOutperform$125.00 ➝ $131.00Low
2/7/2023CitigroupLower TargetBuy$133.00 ➝ $131.00Low
2/7/2023BarclaysLower TargetOverweight$136.00 ➝ $131.00Low
2/7/2023Piper SandlerLower TargetNeutral$103.00 ➝ $95.00Low
2/3/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$120.00 ➝ $130.00Low
11/3/2022Raymond JamesBoost TargetOutperform$125.00 ➝ $135.00Low
11/3/2022JPMorgan Chase & Co.Boost TargetOverweight$138.00 ➝ $143.00Low
11/2/2022MizuhoBoost TargetNeutral$105.00 ➝ $116.00Low
11/2/2022BMO Capital MarketsBoost Target$78.00 ➝ $101.00Low
11/2/2022Morgan StanleyBoost TargetEqual Weight$102.00 ➝ $120.00Low
11/2/2022Wells Fargo & CompanyBoost TargetEqual Weight$110.00 ➝ $120.00Low
11/2/2022Royal Bank of CanadaBoost TargetSector Perform$101.00 ➝ $117.00Low
11/2/2022Cantor FitzgeraldBoost TargetOverweight$127.00 ➝ $132.00Low
11/2/2022Robert W. BairdBoost Target$125.00 ➝ $150.00N/A
11/2/2022Piper SandlerBoost TargetNeutral$91.00 ➝ $103.00N/A
11/2/2022SVB LeerinkBoost TargetMarket Perform$100.00 ➝ $115.00Low
10/24/2022CitigroupBoost TargetBuy$114.00 ➝ $128.00Low
10/20/2022MizuhoBoost TargetNeutral$98.00 ➝ $105.00Low
10/11/2022UBS GroupInitiated CoverageBuy$136.00Low
9/26/2022Wells Fargo & CompanyInitiated CoverageEqual Weight$110.00Low
8/8/2022MizuhoBoost TargetNeutral$95.00 ➝ $98.00Low
8/5/2022Robert W. BairdBoost Target$117.00 ➝ $125.00Low
8/5/2022BarclaysBoost TargetOverweight$110.00 ➝ $113.00Low
7/15/2022Morgan StanleyBoost TargetEqual Weight$100.00 ➝ $102.00Low
4/28/2022WedbushReiterated RatingOutperformHigh
4/12/2022BarclaysBoost TargetOverweight$100.00 ➝ $110.00Medium
4/4/2022JPMorgan Chase & Co.Boost TargetOverweight$125.00 ➝ $126.00Low
3/3/2022Jefferies Financial GroupDowngradeHold$94.00Medium
3/3/2022Piper SandlerDowngradeOverweight ➝ Neutral$114.00 ➝ $94.00High
2/24/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$115.00Low
2/14/2022HC WainwrightReiterated RatingBuy$140.00Low
2/14/2022Morgan StanleyBoost TargetEqual Weight$95.00 ➝ $100.00Medium
2/14/2022MizuhoLower Target$103.00 ➝ $95.00Medium
2/11/2022Raymond JamesReiterated RatingBuy$125.00Medium
2/1/2022Morgan StanleyLower TargetEqual Weight$103.00 ➝ $95.00Low
1/26/2022Piper SandlerLower Target$123.00 ➝ $114.00Low
1/20/2022BarclaysLower TargetOverweight$110.00 ➝ $100.00Low
1/18/2022Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$122.00 ➝ $90.00High
1/7/2022HC WainwrightReiterated RatingBuy$140.00High
1/7/2022Morgan StanleyLower TargetEqual Weight$112.00 ➝ $103.00High
12/8/2021HC WainwrightReiterated RatingBuy$139.00Low
12/8/2021OppenheimerBoost TargetOutperform ➝ Outperform$140.00 ➝ $154.00High
12/8/2021CitigroupBoost TargetBuy ➝ Buy$127.00 ➝ $129.00High
11/18/2021BMO Capital MarketsInitiated CoverageUnderperform$76.00Low
11/17/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$124.00Low
11/2/2021CitigroupLower TargetBuy$132.00 ➝ $127.00High
11/2/2021Raymond JamesLower TargetOutperform$163.00 ➝ $150.00High
11/2/2021Royal Bank of CanadaLower TargetOutperform$130.00 ➝ $119.00High
11/2/2021MizuhoBoost TargetNeutral$99.00 ➝ $103.00High
11/2/2021Cantor FitzgeraldBoost TargetOverweight$117.00 ➝ $123.00High
10/18/2021SVB LeerinkReiterated RatingMarket PerformLow
10/14/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$110.00 ➝ $112.00Low
9/30/2021HC WainwrightReiterated RatingBuyHigh
9/22/2021Needham & Company LLCInitiated CoverageHoldLow
8/4/2021Morgan StanleyLower TargetOverweight$116.00 ➝ $110.00High
7/16/2021HC WainwrightReiterated RatingBuy$140.00Medium
5/18/2021The Goldman Sachs GroupInitiated CoverageNeutral$108.00Low
5/6/2021WedbushLower Target$112.00 ➝ $107.00Medium
5/6/2021OppenheimerLower Target$145.00 ➝ $140.00High
5/6/2021Morgan StanleyLower TargetOverweight$125.00 ➝ $116.00High
5/6/2021SVB LeerinkLower TargetMarket Perform$110.00 ➝ $100.00High
5/6/2021BarclaysUpgradeEqual Weight ➝ Overweight$110.00High
5/3/2021MizuhoLower TargetNeutral$119.00 ➝ $116.00N/A
4/26/2021MizuhoLower TargetIn-Line ➝ Neutral$119.00 ➝ $116.00High
4/19/2021Morgan StanleyBoost TargetOverweight$121.00 ➝ $125.00Low
4/12/2021WedbushLower TargetOutperform$126.00 ➝ $112.00Medium
3/5/2021Robert W. BairdReiterated RatingBuyHigh
2/5/2021MizuhoBoost TargetNeutral$117.00 ➝ $119.00High
2/1/2021Raymond JamesInitiated CoverageOutperform$163.00 ➝ $163.00Low
1/26/2021William BlairReiterated RatingBuyMedium
12/29/2020Cantor FitzgeraldLower TargetOverweight$168.00 ➝ $121.00N/A
12/16/2020Morgan StanleyLower TargetOverweight$133.00 ➝ $121.00Medium
12/7/2020WedbushLower TargetOutperform$129.00 ➝ $121.00High
11/10/2020OppenheimerLower Target$150.00 ➝ $145.00Medium
11/10/2020Smith Barney CitigroupLower Target$149.00 ➝ $138.00Low
11/10/2020William BlairReiterated RatingOutperformLow
11/10/2020WedbushLower TargetOutperform$147.00 ➝ $129.00Medium
11/10/2020Credit Suisse GroupLower TargetNeutral$105.00 ➝ $90.00High
11/10/2020MizuhoLower TargetNeutral$132.00 ➝ $117.00High
11/10/2020SVB LeerinkLower TargetMarket Perform$120.00 ➝ $100.00High
10/29/2020OppenheimerLower TargetOutperform$155.00 ➝ $150.00Low
9/30/2020BenchmarkInitiated CoverageHoldHigh
8/4/2020Credit Suisse GroupLower TargetNeutral$135.00 ➝ $126.00High
8/4/2020Morgan StanleyLower TargetOverweight$149.00 ➝ $146.00High
8/4/2020HC WainwrightBoost TargetBuy$131.00 ➝ $140.00High
8/4/2020Cantor FitzgeraldBoost TargetOverweight$144.00 ➝ $161.00High
8/4/2020MizuhoBoost TargetNeutral$127.00 ➝ $132.00High
8/4/2020SVB LeerinkBoost TargetMarket Perform$105.00 ➝ $120.00High
8/4/2020Piper SandlerBoost TargetOverweight$141.00 ➝ $145.00High
8/4/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$136.00High
7/23/2020MizuhoBoost TargetNeutral$105.00 ➝ $127.00Medium
7/20/2020Credit Suisse GroupBoost TargetNeutral$101.00 ➝ $135.00Medium
7/17/2020OppenheimerBoost TargetOutperform$142.00 ➝ $152.00Medium
7/15/2020Morgan StanleyBoost TargetOverweight$120.00 ➝ $149.00Low
6/29/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$135.00High
6/26/2020CitigroupBoost TargetBuy$124.00 ➝ $149.00High
6/18/2020JPMorgan Chase & Co.Boost TargetIn-Line ➝ Overweight$122.00 ➝ $134.00Medium
6/18/2020Royal Bank of CanadaBoost TargetOutperform$116.00 ➝ $135.00Low
6/17/2020HC WainwrightReiterated RatingBuy$125.00 ➝ $131.00Low
6/16/2020Needham & Company LLCInitiated CoverageHoldLow
6/16/2020OppenheimerInitiated CoverageBuy$142.00Low
6/8/2020WedbushInitiated CoverageOutperform$147.00Low
6/1/2020Piper SandlerReiterated RatingBuy$126.00Low
5/7/2020BarclaysBoost TargetEqual Weight$105.00 ➝ $108.00High
5/7/2020MizuhoBoost TargetNeutral$103.00 ➝ $105.00High
5/7/2020Morgan StanleyLower TargetBuy$121.00 ➝ $120.00High
5/7/2020HC WainwrightReiterated RatingBuy$125.00High
5/7/2020Needham & Company LLCReiterated RatingHoldHigh
4/30/2020William BlairReiterated RatingBuyHigh
4/27/2020Needham & Company LLCReiterated RatingHoldMedium
4/13/2020OppenheimerLower TargetOutperform$132.00 ➝ $130.00Low
4/8/2020Piper SandlerLower Target$147.00 ➝ $125.00Medium
4/8/2020Needham & Company LLCReiterated RatingHold ➝ NeutralMedium
4/8/2020Royal Bank of CanadaReiterated RatingBuy$104.00Medium
3/5/2020CitigroupInitiated CoverageBuy$124.00Medium
2/27/2020BarclaysInitiated CoverageEqual Weight$105.00High
2/24/2020William BlairInitiated CoverageOutperform$116.00High
2/14/2020Stifel NicolausReiterated RatingBuy$127.00N/A
2/5/2020MizuhoInitiated CoverageNeutral$107.00Low
2/5/2020HC WainwrightReiterated RatingBuy$102.00 ➝ $125.00Medium
1/20/2020Royal Bank of CanadaReiterated RatingBuy$125.00Low
1/17/2020Morgan StanleyBoost TargetOverweight$120.00 ➝ $121.00Medium
1/13/2020OppenheimerBoost TargetOutperform$115.00 ➝ $132.00High
12/17/2019Morgan StanleyBoost TargetOverweight$110.00 ➝ $120.00Medium
12/13/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$110.00Low
12/12/2019Piper Jaffray CompaniesReiterated RatingOverweight$116.00 ➝ $153.00Medium
11/5/2019Piper Jaffray CompaniesBoost Target$111.00 ➝ $116.00Low
9/6/2019Royal Bank of CanadaSet TargetBuy$118.00Medium
8/7/2019Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$118.00Low
7/31/2019Needham & Company LLCReiterated RatingHoldMedium
7/30/2019Credit Suisse GroupBoost TargetOutperform$95.00 ➝ $110.00High
7/30/2019Piper Jaffray CompaniesBoost TargetOverweight$103.00 ➝ $111.00High
7/16/2019CIBCInitiated CoverageOutperform ➝ Outperform$100.00Low
7/16/2019OppenheimerInitiated CoverageOutperform$100.00Low
7/15/2019Stifel NicolausSet TargetBuy$113.00Low
6/4/2019GuggenheimInitiated CoverageNeutral ➝ Neutral$88.00Medium
5/20/2019Credit Suisse GroupInitiated CoverageOutperform$95.00Medium
4/22/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$100.00 ➝ $106.00High
4/11/2019Evercore ISIInitiated CoverageOutperformLow
3/29/2019BarclaysReiterated RatingBuy$110.00High
3/13/2019OppenheimerBoost TargetOutperform$105.00 ➝ $110.00Medium
2/6/2019Bank of AmericaLower TargetBuy$124.00 ➝ $117.00Medium
2/6/2019Cantor FitzgeraldReiterated RatingOverweightHigh
1/30/2019HC WainwrightReiterated RatingBuyMedium
1/29/2019Cantor FitzgeraldReiterated RatingBuy$121.00Medium
1/29/2019OppenheimerSet TargetBuy$105.00Medium
1/24/2019Needham & Company LLCDowngradeBuy ➝ HoldLow
1/23/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$97.00 ➝ $100.00Medium
1/15/2019HC WainwrightReiterated RatingBuy$102.00High
1/6/2019OppenheimerSet TargetBuy$105.00High
12/13/2018OppenheimerLower TargetOutperform$140.00 ➝ $105.00Low
12/13/2018JPMorgan Chase & Co.Lower TargetOverweight$127.00 ➝ $97.00Low
12/13/2018Robert W. BairdLower TargetOutperform$131.00 ➝ $96.00Medium
12/13/2018SVB LeerinkLower TargetMarket Perform$110.00 ➝ $84.00Medium
12/13/2018HC WainwrightReiterated RatingBuy$162.00Medium
12/13/2018The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$103.00Medium
12/13/2018BarclaysReiterated RatingBuy$95.00Medium
12/12/2018Stifel NicolausLower TargetBuy$115.00 ➝ $17.07High
12/12/2018Cantor FitzgeraldReiterated RatingBuy$121.00High
12/12/2018Needham & Company LLCSet TargetBuy$104.00High
12/11/2018OppenheimerSet TargetBuy$140.00High
12/5/2018Cantor FitzgeraldSet TargetBuy$150.00Low
11/12/2018SVB LeerinkInitiated CoverageMarket Perform$110.00High
11/6/2018Morgan StanleyLower TargetOverweight ➝ Buy$145.00 ➝ $135.00Low
11/6/2018Piper Jaffray CompaniesSet TargetBuy$111.00High
11/5/2018Cantor FitzgeraldSet TargetBuy$150.00High
11/5/2018OppenheimerSet TargetBuy$140.00High
10/5/2018Piper Jaffray CompaniesSet TargetBuy$115.00Low
(Data available from 10/3/2018 forward)

News Sentiment Rating

1.05 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 12 positive mentions
  • 7 negative mentions
  • 1 very negative mentions
  • 14 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 15 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 12 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 18 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 15 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 20 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 25 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 25 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Neurocrine Biosciences logo
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $110.15
Low: $110.07
High: $111.89

50 Day Range

MA: $108.18
Low: $100.38
High: $117.10

52 Week Range

Now: $110.15
Low: $89.04
High: $129.29


89,690 shs

Average Volume

754,548 shs

Market Capitalization

$10.76 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Neurocrine Biosciences?

The following Wall Street sell-side analysts have issued research reports on Neurocrine Biosciences in the last twelve months: Barclays PLC, BMO Capital Markets, Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., Evercore ISI, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus,, SVB Leerink LLC, SVB Securities, TheStreet, UBS Group AG, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for NBIX.

What is the current price target for Neurocrine Biosciences?

23 Wall Street analysts have set twelve-month price targets for Neurocrine Biosciences in the last year. Their average twelve-month price target is $128.52, suggesting a possible upside of 16.7%. Oppenheimer Holdings Inc. has the highest price target set, predicting NBIX will reach $154.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $95.00 for Neurocrine Biosciences in the next year.
View the latest price targets for NBIX.

What is the current consensus analyst rating for Neurocrine Biosciences?

Neurocrine Biosciences currently has 5 hold ratings and 16 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for NBIX.

What other companies compete with Neurocrine Biosciences?

Other companies that are similar to Neurocrine Biosciences include Repligen, Exelixis, Halozyme Therapeutics, Biogen and Seagen. Learn More about companies similar to Neurocrine Biosciences.

How do I contact Neurocrine Biosciences' investor relations team?

Neurocrine Biosciences' physical mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company's listed phone number is (858) 617-7600 and its investor relations email address is [email protected]. The official website for Neurocrine Biosciences is Learn More about contacing Neurocrine Biosciences investor relations.